Compare Stocks: GMTX, SLN, BLU, and PFNX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BLU BELLUS Health		C$0.00	C$8.58 ▼ C$19.90	C$2.47B	-0.28	59,471 shs	28,666 shs
GMTX Gemini Therapeutics	$80.20 +0.2%	$75.10	$1.16 ▼ $14.10	$3.47B	-0.12	189,291 shs	337,171 shs
PFNX Pfenex	$12.75	$12.75	$5.26 ▼ $14.00	$437.29M	N/A	503,865 shs	N/A
SLN Silence Therapeutics	$13.61 -3.5%	$10.57	$4.19 ▼ $17.58	$666.18M	1.39	1.93 million shs	977,200 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BLU BELLUS Health	0.00%	0.00%	0.00%	0.00%	0.00%
GMTX Gemini Therapeutics	+0.19%	-1.24%	+5.32%	+19.65%	+36.30%
PFNX Pfenex	0.00%	0.00%	0.00%	0.00%	0.00%
SLN Silence Therapeutics	-3.48%	+0.22%	+29.74%	+109.71%	+146.56%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BLU BELLUS Health		C$0.00	C$8.58 ▼ C$19.90	C$2.47B	-0.28	59,471 shs	28,666 shs
GMTX Gemini Therapeutics	$80.20 +0.2%	$75.10	$1.16 ▼ $14.10	$3.47B	-0.12	189,291 shs	337,171 shs
PFNX Pfenex	$12.75	$12.75	$5.26 ▼ $14.00	$437.29M	N/A	503,865 shs	N/A
SLN Silence Therapeutics	$13.61 -3.5%	$10.57	$4.19 ▼ $17.58	$666.18M	1.39	1.93 million shs	977,200 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BLU BELLUS Health	0.00%	0.00%	0.00%	0.00%	0.00%
GMTX Gemini Therapeutics	+0.19%	-1.24%	+5.32%	+19.65%	+36.30%
PFNX Pfenex	0.00%	0.00%	0.00%	0.00%	0.00%
SLN Silence Therapeutics	-3.48%	+0.22%	+29.74%	+109.71%	+146.56%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BLU BELLUS Health	0.00	N/A	N/A	N/A
GMTX Gemini Therapeutics	0.00	N/A	N/A	N/A
PFNX Pfenex	0.00	N/A	N/A	N/A
SLN Silence Therapeutics	2.83	Moderate Buy	$53.50	293.09% Upside

Current Analyst Ratings Breakdown

Latest GMTX, SLN, BLU, and PFNX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2026	SLN Silence Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$25.00 ➝ $32.00
7/17/2026	SLN Silence Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/24/2026	SLN Silence Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight
6/17/2026	SLN Silence Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$75.00

(Data available from 8/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BLU BELLUS Health	C$16K	0.00	N/A	4.67	C$2.91 per share	0.00
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	$2.89 per share	N/A
PFNX Pfenex	N/A	N/A	N/A	N/A	N/A	N/A
SLN Silence Therapeutics	$560K	1,148.34	N/A	N/A	$0.81 per share	16.80

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BLU BELLUS Health	-C$86.79M	-C$0.96	N/A	N/A	N/A	N/A	-26.76%	-16.70%	N/A
GMTX Gemini Therapeutics	-$71.87M	-$1.00	N/A	N/A	N/A	N/A	-38.78%	-35.88%	N/A
PFNX Pfenex	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SLN Silence Therapeutics	-$88.61M	-$1.28	N/A	N/A	N/A	-8,943.86%	-106.94%	-47.99%	11/5/2026 (Estimated)

Latest GMTX, SLN, BLU, and PFNX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/10/2026	Q2 2026	SLN Silence Therapeutics	-$0.1387	-$0.26	-$0.1213	-$0.27	$1.13 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BLU BELLUS Health	N/A	N/A	N/A	N/A	N/A
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	N/A
PFNX Pfenex	N/A	N/A	N/A	N/A	N/A
SLN Silence Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BLU BELLUS Health	0.32	33.42	16.40
GMTX Gemini Therapeutics	N/A	71.49	71.49
PFNX Pfenex	N/A	N/A	N/A
SLN Silence Therapeutics	N/A	7.42	7.42

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BLU BELLUS Health	90.41%
GMTX Gemini Therapeutics	75.42%
PFNX Pfenex	N/A
SLN Silence Therapeutics	98.73%

Insider Ownership

Company	Insider Ownership
BLU BELLUS Health	10.26%
GMTX Gemini Therapeutics	12.90%
PFNX Pfenex	N/A
SLN Silence Therapeutics	3.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BLU BELLUS Health	74	126.81 million	N/A	Not Optionable
GMTX Gemini Therapeutics	30	43.33 million	37.74 million	Not Optionable
PFNX Pfenex	71	34.30 million	N/A	Not Optionable
SLN Silence Therapeutics	100	47.25 million	45.83 million	Not Optionable

GMTX, SLN, BLU, and PFNX Headlines

Recent News About These Companies

Research Analysts Issue Forecasts for SLN Q3 Earnings

2 hours ago | americanbankingnews.com

Silence Therapeutics: Making Some Recent Noise

August 19 at 6:29 PM | seekingalpha.com

Silence Therapeutics (NASDAQ:SLN) Sees Strong Trading Volume - Should You Buy?

August 18 at 11:39 AM | marketbeat.com

What is HC Wainwright's Estimate for SLN Q3 Earnings?

August 18 at 7:11 AM | marketbeat.com

Investors Buy High Volume of Silence Therapeutics Call Options (NASDAQ:SLN)

August 17 at 1:59 PM | marketbeat.com

Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional ADSs

August 14, 2026 | businesswire.com

Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional ADSs

August 14, 2026 | cityam.com

Wall Street Analysts Predict a 140.06% Upside in Silence Therapeutics (SLN): Here's What You Should Know

August 13, 2026 | zacks.com

Analysts Are Bullish on Top Healthcare Stocks: MoonLake Immunotherapeutics (MLTX), Silence Therapeutics (SLN)

August 12, 2026 | theglobeandmail.com

Silence Therapeutics (SLN) Receives a Buy from Morgan Stanley

August 12, 2026 | theglobeandmail.com

Silence Therapeutics (NASDAQ:SLN) Shares Down 6.9% - What's Next?

August 12, 2026 | marketbeat.com

Analysts Conflicted on These Healthcare Names: Silence Therapeutics (SLN), Hims & Hers Health (HIMS) and Syndax Pharmaceuticals (SNDX)

August 12, 2026 | theglobeandmail.com

Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering

August 11, 2026 | businesswire.com

Morgan Stanley maintains Overweight rating on Silence Therapeutics

August 11, 2026 | seekingalpha.com

Silence Therapeutics (NASDAQ:SLN) Sees Unusually-High Trading Volume - What's Next?

August 11, 2026 | marketbeat.com

Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Given Consensus Rating of "Moderate Buy" by Analysts

August 11, 2026 | americanbankingnews.com

Silence Therapeutics plc (SLN) Discusses Top-Line Results From SANRECO Phase II Trial of Divesiran in Polycythemia Vera - Slideshow

August 11, 2026 | seekingalpha.com

Silence Therapeutics’ Divesiran Hits Phase II Goal, Sets Up Phase III PV Trial

August 11, 2026 | marketbeat.com

Silence Therapeutics plc (SLN) Discusses Top-Line Results From SANRECO Phase II Trial of Divesiran in Polycythemia Vera Transcript

August 10, 2026 | seekingalpha.com

Silence Therapeutics' Divesiran to Treat Polychthemia Vera Meets Primary, Secondary Endpoints

August 10, 2026 | finance.yahoo.com

Silence Therapeutics stock surges as divesiran trial results fuel optimism

August 10, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

GMTX, SLN, BLU, and PFNX Company Descriptions

BELLUS Health TSE:BLU

BluEnergies Ltd. is a Canadian based oil and gas exploration and development company focused on offshore West Africa. The Company has recently partnered with TotalEnergies to explore its basin floor fan plays in Blocks LB-26, LB-30, and LB-31 covering an area of approximately 8,924 square kilometers (~2.2 million acres) located in the Harper Basin, in the deep-water offshore Liberia. Additionally, the Company recently acquired a previously discovered and tested sand channel play offshore Louisiana in the shallow water Gulf of America.

Gemini Therapeutics NASDAQ:GMTX

$80.20 +0.15 (+0.19%)

As of 08/18/2026

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Pfenex NYSEAMERICAN:PFNX

$12.75 0.00 (0.00%)

As of 10/1/2020

Pfenex Inc., a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidates include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that have completed Phase Ia clinical study. The company also develops PF582, a biosimilar candidate to Lucentis; PF529, a biosimilar to Neulasta; and hematology/oncology products, including PF743, a recombinant crisantaspase, as well as PF745, a recombinant crisantaspase with half-life extension technology. In addition, it has license and supply agreements for CRM197, a non-toxic mutant of diphtheria toxin. Pfenex Inc. is headquartered in San Diego, California.

Silence Therapeutics NASDAQ:SLN

$13.61 -0.49 (-3.48%)

Closing price 08/19/2026 04:00 PM Eastern

Extended Trading

$13.81 +0.20 (+1.50%)

As of 04:01 AM Eastern

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GMTX, SLN, BLU, and PFNX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GMTX, SLN, BLU, and PFNX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GMTX, SLN, BLU, and PFNX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

GMTX, SLN, BLU, and PFNX Company Descriptions

BELLUS Health TSE:BLU

Gemini Therapeutics NASDAQ:GMTX

Pfenex NYSEAMERICAN:PFNX

Silence Therapeutics NASDAQ:SLN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GMTX, SLN, BLU, and PFNX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GMTX, SLN, BLU, and PFNX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GMTX, SLN, BLU, and PFNX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

GMTX, SLN, BLU, and PFNX Company Descriptions

BELLUS Health TSE:BLU

Gemini Therapeutics NASDAQ:GMTX

Pfenex NYSEAMERICAN:PFNX

Silence Therapeutics NASDAQ:SLN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools